Initial experiences on intravesical gemcitabine instillation followed by Bacillus Calmette-Guerin (BCG) therapy for treating intermediate or high risk patients with superficial bladder cancer

Jong Wook Kim, Dae Yeon Cho, Jeong Kyun Yeo, Hong Seok Park, Duck Ki Yoon

Research output: Contribution to journalArticle

Abstract

Purpose: To investigate the safety and the efficacy of intravesical gemcitabine therapy, we prospectively studied intravesical gemcitabine instillation followed by Bacillus Calmette-Guerin (BCG) instillation for treating the patients who suffer from superficial bladder cancer, and the above method was then compared with conventional BCG instillation. Materials and Methods: Between May 2005 and April 2007, a total of 84 patients were divided into Group I: the patients were treated with a 2-week course of gemcitabine (1,000mg/50ml, 2,000mg/50ml) followed by a conventional 6-week course of BCG, and Group II: the patients were treated by BCG instillation only. Gemcitabine was instilled immediately within 6 hours after complete trans-urethral resection of the bladder tumor (TURBT) and then this was repeated one week later. BCG instillation was started 2 weeks after TURBT. The complications, recurrence rates, progression rates and recurrence-free period (RFP) were analyzed in both groups. Results: The treatment was well tolerated in all the patients. Most of the complications were self-limiting, and there was no significant difference between the two groups (p=0.379). The recurrence rates of the two groups were 25.6% and 26.7%, respectively (p=0.899). Yet the recurrence-free period (RFP) was significantly longer in Group I (p=0.021). The progression rates of the two groups were 2.6% and 6.7%, respectively (p=0.620). Conclusions: Intravesical gemcitabine instillation showed the effect to prolong the recurrence-free period for patients with superficial bladder cancer. Further long-term study will be needed.

Original languageEnglish
Pages (from-to)313-319
Number of pages7
JournalKorean Journal of Urology
Volume49
Issue number4
DOIs
Publication statusPublished - 2008 Apr 1

Fingerprint

gemcitabine
Intravesical Administration
Mycobacterium bovis
Urinary Bladder Neoplasms
Recurrence
Therapeutics
Safety

Keywords

  • Bladder cancer
  • Gemcitabine
  • Intravesical installation

ASJC Scopus subject areas

  • Urology

Cite this

Initial experiences on intravesical gemcitabine instillation followed by Bacillus Calmette-Guerin (BCG) therapy for treating intermediate or high risk patients with superficial bladder cancer. / Kim, Jong Wook; Cho, Dae Yeon; Yeo, Jeong Kyun; Park, Hong Seok; Yoon, Duck Ki.

In: Korean Journal of Urology, Vol. 49, No. 4, 01.04.2008, p. 313-319.

Research output: Contribution to journalArticle

@article{80c425e2a02c4a028c65ccc0763b0601,
title = "Initial experiences on intravesical gemcitabine instillation followed by Bacillus Calmette-Guerin (BCG) therapy for treating intermediate or high risk patients with superficial bladder cancer",
abstract = "Purpose: To investigate the safety and the efficacy of intravesical gemcitabine therapy, we prospectively studied intravesical gemcitabine instillation followed by Bacillus Calmette-Guerin (BCG) instillation for treating the patients who suffer from superficial bladder cancer, and the above method was then compared with conventional BCG instillation. Materials and Methods: Between May 2005 and April 2007, a total of 84 patients were divided into Group I: the patients were treated with a 2-week course of gemcitabine (1,000mg/50ml, 2,000mg/50ml) followed by a conventional 6-week course of BCG, and Group II: the patients were treated by BCG instillation only. Gemcitabine was instilled immediately within 6 hours after complete trans-urethral resection of the bladder tumor (TURBT) and then this was repeated one week later. BCG instillation was started 2 weeks after TURBT. The complications, recurrence rates, progression rates and recurrence-free period (RFP) were analyzed in both groups. Results: The treatment was well tolerated in all the patients. Most of the complications were self-limiting, and there was no significant difference between the two groups (p=0.379). The recurrence rates of the two groups were 25.6{\%} and 26.7{\%}, respectively (p=0.899). Yet the recurrence-free period (RFP) was significantly longer in Group I (p=0.021). The progression rates of the two groups were 2.6{\%} and 6.7{\%}, respectively (p=0.620). Conclusions: Intravesical gemcitabine instillation showed the effect to prolong the recurrence-free period for patients with superficial bladder cancer. Further long-term study will be needed.",
keywords = "Bladder cancer, Gemcitabine, Intravesical installation",
author = "Kim, {Jong Wook} and Cho, {Dae Yeon} and Yeo, {Jeong Kyun} and Park, {Hong Seok} and Yoon, {Duck Ki}",
year = "2008",
month = "4",
day = "1",
doi = "10.4111/kju.2008.49.4.313",
language = "English",
volume = "49",
pages = "313--319",
journal = "Korean Journal of Urology",
issn = "2005-6737",
publisher = "Korean Urological Association",
number = "4",

}

TY - JOUR

T1 - Initial experiences on intravesical gemcitabine instillation followed by Bacillus Calmette-Guerin (BCG) therapy for treating intermediate or high risk patients with superficial bladder cancer

AU - Kim, Jong Wook

AU - Cho, Dae Yeon

AU - Yeo, Jeong Kyun

AU - Park, Hong Seok

AU - Yoon, Duck Ki

PY - 2008/4/1

Y1 - 2008/4/1

N2 - Purpose: To investigate the safety and the efficacy of intravesical gemcitabine therapy, we prospectively studied intravesical gemcitabine instillation followed by Bacillus Calmette-Guerin (BCG) instillation for treating the patients who suffer from superficial bladder cancer, and the above method was then compared with conventional BCG instillation. Materials and Methods: Between May 2005 and April 2007, a total of 84 patients were divided into Group I: the patients were treated with a 2-week course of gemcitabine (1,000mg/50ml, 2,000mg/50ml) followed by a conventional 6-week course of BCG, and Group II: the patients were treated by BCG instillation only. Gemcitabine was instilled immediately within 6 hours after complete trans-urethral resection of the bladder tumor (TURBT) and then this was repeated one week later. BCG instillation was started 2 weeks after TURBT. The complications, recurrence rates, progression rates and recurrence-free period (RFP) were analyzed in both groups. Results: The treatment was well tolerated in all the patients. Most of the complications were self-limiting, and there was no significant difference between the two groups (p=0.379). The recurrence rates of the two groups were 25.6% and 26.7%, respectively (p=0.899). Yet the recurrence-free period (RFP) was significantly longer in Group I (p=0.021). The progression rates of the two groups were 2.6% and 6.7%, respectively (p=0.620). Conclusions: Intravesical gemcitabine instillation showed the effect to prolong the recurrence-free period for patients with superficial bladder cancer. Further long-term study will be needed.

AB - Purpose: To investigate the safety and the efficacy of intravesical gemcitabine therapy, we prospectively studied intravesical gemcitabine instillation followed by Bacillus Calmette-Guerin (BCG) instillation for treating the patients who suffer from superficial bladder cancer, and the above method was then compared with conventional BCG instillation. Materials and Methods: Between May 2005 and April 2007, a total of 84 patients were divided into Group I: the patients were treated with a 2-week course of gemcitabine (1,000mg/50ml, 2,000mg/50ml) followed by a conventional 6-week course of BCG, and Group II: the patients were treated by BCG instillation only. Gemcitabine was instilled immediately within 6 hours after complete trans-urethral resection of the bladder tumor (TURBT) and then this was repeated one week later. BCG instillation was started 2 weeks after TURBT. The complications, recurrence rates, progression rates and recurrence-free period (RFP) were analyzed in both groups. Results: The treatment was well tolerated in all the patients. Most of the complications were self-limiting, and there was no significant difference between the two groups (p=0.379). The recurrence rates of the two groups were 25.6% and 26.7%, respectively (p=0.899). Yet the recurrence-free period (RFP) was significantly longer in Group I (p=0.021). The progression rates of the two groups were 2.6% and 6.7%, respectively (p=0.620). Conclusions: Intravesical gemcitabine instillation showed the effect to prolong the recurrence-free period for patients with superficial bladder cancer. Further long-term study will be needed.

KW - Bladder cancer

KW - Gemcitabine

KW - Intravesical installation

UR - http://www.scopus.com/inward/record.url?scp=43249107786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43249107786&partnerID=8YFLogxK

U2 - 10.4111/kju.2008.49.4.313

DO - 10.4111/kju.2008.49.4.313

M3 - Article

AN - SCOPUS:43249107786

VL - 49

SP - 313

EP - 319

JO - Korean Journal of Urology

JF - Korean Journal of Urology

SN - 2005-6737

IS - 4

ER -